Navidea Biopharmaceuticals Inc (NAVB) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access NAVB Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Navidea Biopharmaceuticals Inc adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent3.86
Cash & Short-term Investments3.00
Inventories0.46
Other Current Assets0.03
Prepaid Expense And Other Assets Current0.15
Total Current Assets4.50
Equipment/Property/Plant Net0.11
Intangible Assets1.06
Other Assets, Noncurrent0.02
Total Assets5.70
Liabilities
Accounts Payable, Current AC0.00
Accrued Liabilities And Other Liabilities3.85
Notes Payable, Current NO0.00
Other Liabilities, Current3.33
Deferred Revenue, Current DE0.80
Total Current Liabilities7.98
Long-term debt0.00
Total Long-term Debt0.00
Other liabilities, Noncurrent0.70
Terminated Lease Liability Current0.01
Total Liabilities8.68
Stockholders' Equity
Common Stock Value0.29
Additional Paid In Capital Common Stock382.35
Retained Earnings / Accumulated Deficit-385.91
Other Equity0.00
Common Stockholder's Equity-3.27
Non-controlling interests & other0.29
Total Stockholder's Equity-2.98
Liabilities & Stockholder's Equity5.70
4 historic quarters locked

Sign in to unlock the full Navidea Biopharmaceuticals Inc balance sheet history.

About Navidea Biopharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001437749-23-032052

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.